Clavulanic acid
Amoxicillin / Clavulanate Potassium, Augmentin, Timentin (clavulanic acid) is a small molecule pharmaceutical. Clavulanic acid was first approved as Augmentin '250' on 1984-08-06. It is used to treat haemophilus infections, otitis media, and staphylococcal infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| otorhinolaryngologic diseases | D010038 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amoclan | 2009-01-07 | |
| amoxicillan and clavulanate potassium | ANDA | 2014-08-01 |
| amoxicillin | ANDA | 2020-06-19 |
| amoxicillin amoxicillin and clavulanate potassium | ANDA | 2024-01-09 |
| amoxicillin and clavulanate potassium | ANDA | 2024-11-20 |
| amoxicillin and clavulanate potassium extended release | New Drug Application | 2011-04-07 |
| amoxicillin clavulanate potassium | 2006-11-03 | |
| augmentin | New Drug Application | 2024-05-16 |
| augmentin es-600 | New Drug Application | 2022-10-28 |
| augmentinxr | New Drug Application | 2010-11-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
326 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 2 | 6 | 20 | 25 | 17 | 66 |
| Communicable diseases | D003141 | — | — | 1 | 3 | 12 | 14 | 10 | 39 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 5 | 14 | 11 | 4 | 31 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | 5 | 14 | 8 | 27 |
| Appendicitis | D001064 | EFO_0007149 | K37 | 1 | 1 | 2 | 4 | 14 | 22 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | 2 | 4 | 5 | 4 | 15 |
| Otitis | D010031 | — | — | — | 2 | 4 | 6 | 3 | 15 |
| Rhinosinusitis | D000096825 | — | — | — | 1 | 1 | 5 | 5 | 12 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 6 | 3 | 3 | 12 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 8 | — | 1 | 1 | 11 |
Show 85 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 3 | 5 | — | — | 6 |
| Intraabdominal infections | D059413 | — | — | — | 1 | 5 | — | — | 6 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 2 | — | 2 | — | 1 | 5 |
| Neutropenia | D009503 | — | D70 | — | — | 3 | — | 2 | 5 |
| Covid-19 | D000086382 | — | — | — | — | 2 | — | 2 | 4 |
| Abscess | D000038 | EFO_0003030 | — | — | — | 3 | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 2 | — | 1 | 4 |
| Cholecystitis | D002764 | HP_0001082 | K81 | — | — | 1 | — | 2 | 3 |
| Acalculous cholecystitis | D042101 | EFO_1000790 | — | — | — | 1 | — | 2 | 3 |
| Hyperthermia | D000084462 | — | — | — | — | 2 | — | 1 | 3 |
Show 51 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 6 | — | — | — | 6 |
| Cocaine-related disorders | D019970 | — | F14 | 3 | 1 | — | — | — | 4 |
| Drug therapy | D004358 | — | — | — | 1 | — | — | 1 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 1 | 2 |
| Empyema | D004653 | EFO_0003097 | — | — | 1 | — | — | 1 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 1 | 2 |
| Depression | D003863 | — | F33.9 | — | 2 | — | — | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | — | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | — | — | — | 2 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 1 | — | — | — | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | 5 | 13 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 1 | — | — | — | 2 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | 2 | 3 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | 1 | — | — | — | 1 | 2 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 4 | 4 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 2 | 2 |
| Acute cholecystitis | D041881 | EFO_1001289 | K81.0 | — | — | — | — | 2 | 2 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 2 | 2 |
| Enterococcus | D016983 | — | — | — | — | — | — | 2 | 2 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | — | 2 | 2 |
| Tonsillitis | D014069 | HP_0011110 | J03 | — | — | — | — | 2 | 2 |
| Thyroid nodule | D016606 | EFO_1001436 | — | — | — | — | — | 2 | 2 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | — | — | — | 2 | 2 |
Show 65 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clavulanic acid |
| INN | clavulanic acid |
| Description | Clavulanic acid is antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes. It has a role as an antibacterial drug, a bacterial metabolite, an anxiolytic drug and an EC 3.5.2.6 (beta-lactamase) inhibitor. It is a conjugate acid of a clavulanate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21 |
Identifiers
| PDB | — |
| CAS-ID | 58001-44-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL777 |
| ChEBI ID | 48947 |
| PubChem CID | 5280980 |
| DrugBank | DB00766 |
| UNII ID | 23521W1S24 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Clavulanic acid
+
Amoxicillin
+
Clavulanate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 44,175 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
34,806 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use